Literature DB >> 32969503

Prevalence of mucocutaneous manifestations in 666 patients with COVID-19 in a field hospital in Spain: oral and palmoplantar findings.

A Nuno-Gonzalez1,2, P Martin-Carrillo3,4, K Magaletsky1,2, M D Martin Rios5, C Herranz Mañas1, J Artigas Almazan1, G García Casasola6,7, E Perez Castro4, A Gallego Arenas8, A Mayor Ibarguren1,2, M Feito Rodríguez1,2, B Lozano Masdemont9, M Beato10, E Ruiz Bravo10, P Oliver11, M D Montero Vega12, P Herranz Pinto1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32969503      PMCID: PMC7537506          DOI: 10.1111/bjd.19564

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


× No keyword cloud information.
Dear Editor, Coronavirus disease 2019 (COVID‐19) has been associated with several cutaneous manifestations.– A temporary field hospital was implemented during the pandemic peak in Madrid, Spain, to attend patients with COVID‐19 who had mild‐to‐moderate pneumonia. A team of dermatologists working as medical volunteers performed a cross‐sectional study between 10 and 25 April 2020 to evaluate cutaneous findings of such patients. A total of 666 patients with COVID‐19 fulfilled the inclusion criteria: either positive real‐time reverse‐transcription polymerase chain reaction (RT‐PCR) testing for SARS‐CoV‐2, or bilateral pneumonia. Mean age was 55·7 years; with a slight female predominance (58%). Notably, 47·1% were from Latin America. Overall, 304 (45·7%) of our patients presented with one or more mucocutaneous manifestations. Oral cavity findings were seen in 78 cases (25·7%), including transient lingual papillitis (11·5%), glossitis with lateral indentations (6·6%) (Figure 1a), aphthous stomatitis (6·9%), glossitis with patchy depapillation (3·9%) (Figure 1b) and mucositis (3·9%). Burning sensation was reported in 5·3% of patients, and taste disturbances (dysgeusia) were commonly associated.
Figure 1

Upper panel shows COVID‐19 oral mucosa findings. (a) Glossitis with lateral indentations and anterior transient lingual papillitis due to swelling of the tongue and friction with the teeth. (b) Glossitis with patchy depapillation. Lower panel shows palmoplantar findings in patients with COVID‐19. (c) Reddish‐to‐brown acral macules with a slight desquamation on the feet of a patient. Pathology excluded racial pigmentation, showing mild‐to‐moderate lymphocytic infiltrate surrounding the blood vessels and eccrine sweat glands. (d) Acral macules on the palm of a patient with COVID‐19 with the same histopathology.

Upper panel shows COVID‐19 oral mucosa findings. (a) Glossitis with lateral indentations and anterior transient lingual papillitis due to swelling of the tongue and friction with the teeth. (b) Glossitis with patchy depapillation. Lower panel shows palmoplantar findings in patients with COVID‐19. (c) Reddish‐to‐brown acral macules with a slight desquamation on the feet of a patient. Pathology excluded racial pigmentation, showing mild‐to‐moderate lymphocytic infiltrate surrounding the blood vessels and eccrine sweat glands. (d) Acral macules on the palm of a patient with COVID‐19 with the same histopathology. Palmoplantar involvement was observed in 121 patients (39·8%) and included diffuse desquamation in 77 (25·3%), often favouring the weight‐bearing areas, and reddish‐to‐brown acral macules on palms and soles in 46 (15·1%) (Figure 1c, d). Mild pruritus was occasionally reported. Fungal cultures of plantar desquamation performed in nine patients ruled out superficial mycoses. Histological study from the acral macules was performed in four patients, showing a mild‐to‐moderate lymphocytic infiltrate surrounding the blood vessels and eccrine sweat glands. Seven per cent of the patients reported burning sensation (erythrodysesthesia) at the beginning of the disease. Urticaria (6·9%), rash (2·9%) and vesicular eruptions (1·6%) were observed in a minority of patients. While urticaria and rash were observed at any stage of the COVID‐19 infection, vesicular eruptions typically appeared within the first few days of symptoms. Both urticaria and vesicular eruptions appeared in younger patients than did the other mucocutaneous manifestations, with statistical significance (P = 0·024). Prior studies, have found a significantly lower prevalence of COVID‐19‐associated dermatoses (20% and 7·8%, respectively). The higher prevalence in our study may be due to additional findings not previously described. Although the oral cavity is frequently involved in viral infections, glossitis or papillitis have not been described in patients with COVID‐19· However, these differences could also be due to the conditions during hospitalization including ventilation masks, for example. We hypothesize that the contagion risk while examining the oral cavity might have precluded a thorough physical examination in these patients. Palmoplantar involvement was also a frequent finding. Some patients recalled a burning sensation and redness or swelling of the hands or feet shortly after COVID‐19 symptoms began. Erythrodysesthesia is a common complaint secondary to cancer chemotherapy that is thought to be related to direct drug toxicity and inflammation of the eccrine glands. Interestingly, several outbreaks of poxvirus‐related erythromelalgia have been reported in China. The first outbreak occurred in Wuhan in 1987, and all patients had respiratory symptoms as well as redness and swelling of the hands and feet. Also, burning sensation has been described in chilblain‐like lesions and there is one self‐reported case of a physician with COVID‐19 complaining of a ‘pins and needles’ sensation in palms and soles with subsequent appearance of acral macules. Diffuse asymptomatic palmoplantar desquamation was another common but previously unreported finding. Although it could be related to other common conditions such as tinea pedis, patients denied its prior existence and fungal infection was excluded in nine of 121 patients. Skin rashes were relatively uncommon, being observed in 11·6% of our patients. Although a variety of rashes have been previously reported both in children and adults,, the exact prevalence, time of onset and age specificity remains unknown. Interestingly, pseudo‐chilblains have been commonly observed in children (some of them with negative RT‐PCR or serological tests) but were absent in our 666 patients, supporting the age‐specificity trend. Our study has several limitations. Firstly, we only included patients with mild‐to‐moderate COVID‐19 pneumonia and cannot provide data on skin disease in asymptomatic patients or with more severe forms of COVID‐19. Secondly, all patients were adults, and the prevalence of mucocutaneous findings may be different in children. Thirdly, as our work was performed in a 2‐week period, we may have missed earlier or late cutaneous manifestations of COVID‐19. In summary, almost half of patients with mild‐to‐moderate COVID‐19 admitted in a field‐hospital during a 2‐week period showed mucocutaneous findings. The oral cavity was frequently involved and deserves specific examination under appropriate circumstances to avoid contagion risk. Redness and swelling of the hands and feet, fine palmoplantar desquamation and reddish‐to‐brown macules can help us to diagnose COVID‐19 infection and should be routinely checked.

Acknowledgments

We would like to thank Dr Angela Hernandez‐Martín for her valuable comments during the preparation of this paper.

Author Contribution

Almudena Nuno‐Gonzalez: Conceptualization (lead); Data curation (lead); Formal analysis (equal); Investigation (lead); Methodology (lead); Project administration (lead); Supervision (lead); Validation (equal); Visualization (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Pilar Martin‐Carrillo: Conceptualization (equal); Data curation (equal); Methodology (equal); Validation (equal); Visualization (equal); Writing‐original draft (equal). Kyrylo Magaletskyy: Investigation (equal); Methodology (equal); Validation (equal); Visualization (equal); Writing‐original draft (equal). Maria Dolores Martin‐Rios: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Supervision (equal); Visualization (equal); Writing‐original draft (equal). Cristina Herranz Mañas: Data curation (equal); Formal analysis (equal); Investigation (equal); Visualization (equal). Jorge Artigas Almazan: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Visualization (equal). Gonzalo Garcia Casasola: Conceptualization (equal); Formal analysis (supporting); Investigation (supporting); Methodology (equal); Resources (equal); Supervision (supporting); Validation (equal); Visualization (equal). Elena Perez Castro: Data curation (equal); Formal analysis (equal); Investigation (equal); Supervision (equal); Validation (supporting); Visualization (supporting). Angela Gallego Arenas: Data curation (equal); Formal analysis (equal); Investigation (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting). Ander Mayor Ibarguren: Formal analysis (supporting); Investigation (equal); Methodology (equal); Supervision (equal); Validation (supporting); Visualization (supporting). Marta Feito Rodríguez: Conceptualization (supporting); Investigation (supporting); Methodology (equal); Supervision (supporting); Validation (supporting); Visualization (equal). Belén Lozano Masdemont: Data curation (equal); Formal analysis (supporting); Methodology (supporting); Validation (equal); Visualization (equal). Maria José Beato: Methodology (supporting); Resources (equal); Supervision (equal); Visualization (supporting). Elena Ruiz Bravo: Methodology (supporting); Resources (equal); Validation (supporting); Visualization (supporting). Paloma Oliver: Data curation (supporting); Methodology (supporting); Resources (equal); Supervision (equal); Validation (supporting); Visualization (supporting). Maria Dolores Montero Vega: Data curation (supporting); Resources (equal); Supervision (supporting); Validation (supporting); Visualization (supporting). Pedro Herranz Pinto: Conceptualization (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Project administration (equal); Resources (supporting); Supervision (equal); Validation (equal); Visualization (equal); Writing‐original draft (equal); Writing‐review & editing (supporting).
  8 in total

1.  Enanthem in Patients With COVID-19 and Skin Rash.

Authors:  Juan Jimenez-Cauhe; Daniel Ortega-Quijano; Dario de Perosanz-Lobo; Patricia Burgos-Blasco; Sergio Vañó-Galván; Montse Fernandez-Guarino; Diego Fernandez-Nieto
Journal:  JAMA Dermatol       Date:  2020-10-01       Impact factor: 10.282

2.  [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].

Authors:  L Hueso; O Sanmartín; E Nagore; R Botella-Estrada; C Requena; B Llombart; C Serra-Guillén; A Alfaro-Rubio; C Guillén
Journal:  Actas Dermosifiliogr       Date:  2008-05

3.  Cutaneous manifestations in COVID-19: a first perspective.

Authors:  S Recalcati
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05       Impact factor: 6.166

4.  Genome sequence of erythromelalgia-related poxvirus identifies it as an ectromelia virus strain.

Authors:  Jorge D Mendez-Rios; Craig A Martens; Daniel P Bruno; Stephen F Porcella; Zhi-Ming Zheng; Bernard Moss
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

5.  Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy.

Authors:  Vincenzo De Giorgi; Sebastiano Recalcati; Ziyi Jia; Wei Chong; Renyu Ding; Yunhua Deng; Federica Scarfi; Federico Venturi; Luciana Trane; Alessia Gori; Flavia Silvestri; Xing-Hua Gao; Torello Lotti
Journal:  J Am Acad Dermatol       Date:  2020-05-19       Impact factor: 11.527

6.  Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients.

Authors:  Angelo Valerio Marzano; Giovanni Genovese; Gabriella Fabbrocini; Paolo Pigatto; Giuseppe Monfrecola; Bianca Maria Piraccini; Stefano Veraldi; Pietro Rubegni; Marco Cusini; Valentina Caputo; Franco Rongioletti; Emilio Berti; Piergiacomo Calzavara-Pinton
Journal:  J Am Acad Dermatol       Date:  2020-04-16       Impact factor: 11.527

7.  Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection.

Authors:  C van Damme; E Berlingin; S Saussez; O Accaputo
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-04       Impact factor: 9.228

8.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

  8 in total
  28 in total

1.  Are Oral Mucosal Changes a Sign of COVID-19? A Cross-Sectional Study at a Field Hospital.

Authors:  A Nuño González; K Magaletskyy; P Martín Carrillo; B Lozano Masdemont; A Mayor Ibarguren; M Feito Rodríguez; P Herranz Pinto
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2021-05-12

2.  [Translated article] Oral Findings in Patients With COVID-19.

Authors:  M Villarroel-Dorrego; L Chacón; R Rosas; V Barrios; Y Pernía; H Vélez
Journal:  Actas Dermosifiliogr       Date:  2022-02

Review 3.  Oral Mucosa, Saliva, and COVID-19 Infection in Oral Health Care.

Authors:  Devi Sewvandini Atukorallaya; Ravindra K Ratnayake
Journal:  Front Med (Lausanne)       Date:  2021-04-22

4.  Oral manifestations accompanying and related to COVID-19: Overlooking the obvious.

Authors:  Gabriela Anaya-Saavedra
Journal:  Oral Dis       Date:  2021-03-26       Impact factor: 4.068

5.  Are Oral Mucosal Changes a Sign of COVID-19? A Cross-Sectional Study at a Field Hospital.

Authors:  A Nuño González; K Magaletskyy; P Martín Carrillo; B Lozano Masdemont; A Mayor Ibarguren; M Feito Rodríguez; P Herranz Pinto
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2021-02-27

Review 6.  COVID-19 and Dentistry in 72 Questions: An Overview of the Literature.

Authors:  Stéphane Derruau; Jérôme Bouchet; Ali Nassif; Alexandre Baudet; Kazutoyo Yasukawa; Sandrine Lorimier; Isabelle Prêcheur; Agnès Bloch-Zupan; Bernard Pellat; Hélène Chardin; Sophie Jung
Journal:  J Clin Med       Date:  2021-02-16       Impact factor: 4.241

7.  The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.

Authors:  Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi
Journal:  J Autoimmun       Date:  2020-12-14       Impact factor: 7.094

Review 8.  Stopping the COVID-19 pandemic in dental offices: A review of SARS-CoV-2 transmission and cross-infection prevention.

Authors:  Maya Hartig; Carley Stephens; Aaron Foster; Douglas Fontes; Michael Kinzel; Franklin García-Godoy
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-03

Review 9.  Skin manifestations of COVID-19 in children: Part 2.

Authors:  D Andina; A Belloni-Fortina; C Bodemer; E Bonifazi; A Chiriac; I Colmenero; A Diociaiuti; M El-Hachem; L Fertitta; D van Gysel; A Hernández-Martín; T Hubiche; C Luca; L Martos-Cabrera; A Maruani; F Mazzotta; A D Akkaya; M Casals; J Ferrando; R Grimalt; I Grozdev; V Kinsler; M A Morren; M Munisami; A Nanda; M P Novoa; H Ott; S Pasmans; C Salavastru; V Zawar; A Torrelo
Journal:  Clin Exp Dermatol       Date:  2020-11-09       Impact factor: 4.481

10.  Could the oral cavity be a target organ in SARS-CoV-2 infection?

Authors:  Satish Kumar
Journal:  Evid Based Dent       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.